Anemia, Blood Transfusion Requirements and Mortality Risk in Human Immunodeficiency Virus-Infected Adults Requiring Acute Medical Admission to Hospital in South Africa

Andrew D. Kerkhoff,1,2 Stephen D. Lawn,3,4,5 Charlotte Schutz,5,6 Rosie Burton,5,7 Andrew Boulle,8,9 Frank J. Cobelens,2,10 and Graeme Meintjes5,6,11

1Department of Medicine, University of California San Francisco School of Medicine and 2Department of Global Health, Academic Medical Center, Amsterdam Institute for Global Health and Development, University of Amsterdam, The Netherlands; 3Faculty of Health Sciences, The Desmond Tutu HIV Centre, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, South Africa; 4Department of Clinical Research, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, United Kingdom; 5Department of Medicine, Faculty of Health Sciences, University of Cape Town; 6Clinical Infectious Diseases Research Initiative, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, 7Khayelitsha District Hospital, Cape Town, 8Faculty of Health Sciences, Centre for Infectious Disease Epidemiology and Research, School of Public Health and Family Medicine, University of Cape Town, and 9Department of Health, Provincial Government of the Western Cape, South Africa; 10KNCV Tuberculosis Foundation, The Hague, The Netherlands; and 11Department of Medicine, Imperial College, London, United Kingdom

Background. Morbidity and mortality remain high among hospitalized patients infected with human immunodeficiency virus (HIV) in sub-Saharan Africa despite widespread availability of antiretroviral therapy. Severe anemia is likely one important driver, and some evidence suggests that blood transfusions may accelerate HIV progression and paradoxically increase short-term mortality. We investigated the relationship between anemia, blood transfusions, and mortality in a South African district hospital.

Methods. Unselected consecutive HIV-infected adults requiring acute medical admission to a Cape Town township district hospital were recruited. Admission hemoglobin concentrations were used to classify anemia severity according to World Health Organization/AIDS Clinical Trials Group criteria. Vital status was determined at 90 days, and Cox regression analyses were used to determine independent predictors of mortality.

Results. Of 585 HIV-infected patients enrolled, 578 (98.8%) were included in the analysis. Anemia was detected in 84.8% of patients and was severe (hemoglobin, 6.5–7.9 g/dL) or life-threatening (hemoglobin, <6.5 g/dL) in 17.3% and 13.3%, respectively. Within 90 days of the date of admission, 13.5% (n = 78) patients received at least 1 blood transfusion with red cell concentrate and 77 (13.3%) patients died. In univariable analysis, baseline hemoglobin and receipt of blood transfusion were associated with increased mortality risk. However, in multivariable analysis, neither hemoglobin nor receipt of a blood transfusion were independently associated with greater mortality risk. Acquired immune deficiency syndrome-defining illnesses other than tuberculosis and impaired renal function independently predicted mortality.

Conclusions. Newly admitted HIV-infected adults had a high prevalence of severe or life-threatening anemia and blood transfusions were frequently required. However, after adjustment for confounders, blood transfusions did not confer an increased mortality risk.

Keywords. Africa; AIDS; anemia; blood transfusion; HIV; hospitalized; mortality.

Despite the unprecedented scale-up of antiretroviral therapy (ART) in sub-Saharan Africa over the last decade, morbidity and mortality among hospitalized inpatient persons infected with human immunodeficiency virus (HIV) remain very high [1, 2]. Anemia is the most common hematological complication of HIV disease, it is highly prevalent among persons living with HIV/acquired immune deficiency syndrome (AIDS)
in sub-Saharan Africa [3–6], and it may be an important driver of morbidity and mortality among inpatients infected with HIV. HIV-related anemia is associated with fatigue, decreased quality of life [7], and a greatly increased mortality risk [8–11]. Although the South African HIV Clinician’s Society has published recommendations on the management of anemia and blood transfusions among patients infected with HIV, there are no normative international guidelines for the management of HIV-related anemia in sub-Saharan Africa or other resource-limited settings [12].

ART is associated with substantial hemoglobin recovery, resulting in resolution of anemia in a majority of HIV-infected African patients without additional specific hematological interventions [3, 5, 6, 13, 14]. ART is thus the key therapeutic intervention for HIV-related chronic anemia, but weeks or months may be required for adequate hemoglobin recovery to occur with ART. However, patients may also present acutely to healthcare settings with severe or life-threatening anemia, requiring immediate correction. This may include administration of blood transfusions when considered clinically appropriate. Although it may be expected that HIV-infected hospitalized patients in sub-Saharan Africa have high transfusion requirements, few data have been published on this topic [15–17]. In addition, some evidence suggests that blood transfusions are associated with modest increases in plasma HIV-1 RNA levels and increased mortality risk [11, 18–20]. This has led some clinicians to conclude that transfusions should be used sparingly among patients infected with HIV [12]. The limited evidence to date to support such caution is derived exclusively from North America, and thus this issue has not yet been investigated in sub-Saharan Africa, where the prevalence of HIV-related anemia remains high. Therefore, we sought to determine whether blood transfusions were independently associated with an increased mortality risk among HIV-infected adults requiring acute medical admission to a district-level hospital in Cape Town, South Africa.

METHODS

GF Jooste Hospital served as the public sector adult referral hospital for a community of approximately 1.3 million people at the time of the study. Patients seen at public sector primary care, HIV, or tuberculosis (TB) clinics or by private general practitioners could be referred to the hospital. Those ill enough to require admission were admitted to the medical ward. The local antenatal HIV seroprevalence is approximately 35%, and the large burden of TB is well described [21, 22]. The Research Ethics Committees of the University of Cape Town and the London School of Hygiene & Tropical Medicine approved this study, and all patients provided written informed consent before participation.

This study was nested within a prospective cohort study in which the parent study sought to evaluate new approaches to the rapid diagnosis of HIV-associated TB [23]. HIV-infected persons ≥18 years of age requiring acute admission to a medical ward were eligible for inclusion. Patients were prospectively recruited 4 days per week from June 2012 to October 2013. Any patient with an unknown or previously negative test was offered HIV testing. A positive HIV serostatus was confirmed in parallel by 2 rapid assays.

Procedures

Upon enrollment, demographic and clinical details were recorded for all patients. Patients were systematically investigated for TB by obtaining a combination of respiratory and non-respiratory clinical specimens as previously described [23]. A venous blood sample was collected for the measurement of C-reactive protein (CRP) and HIV viral load in keeping with the protocol of the parent study. Hemoglobin concentrations were measured using the ADVIA 2120 hematology analyzer (Siemens Healthcare Diagnostics, Erlangen, Germany).

Patient Outcomes and Use of Blood Products

Mortality and loss to follow-up (LTFU) within 90 days after study entry was determined using patient case notes and the medical ward register in addition to 6 regional and national electronic health record databases [24]. All data sources were cross-referenced for consistency, and any discrepancies in patient outcomes were resolved.

The decision to administer a blood transfusion was made by the clinical team responsible for the patient, and there was no hospital guideline defining a recommended hemoglobin “threshold” level for blood transfusion. Electronic records from the local Red Cross Hospital blood bank were searched to identify patients receiving a blood transfusion with red blood cell concentrate (RCC) between 6 months before study enrollment to 6 months after study enrollment (12-month interval). However, because transfusions administered between 7 days prior to and 90 days after the study admission date were most likely to be associated with mortality, only blood transfusion data from this time interval was utilized. Costs associated with blood products and transfusion services were also extracted from billing invoices from the Western Province blood transfusion service. Costs were estimated “top-down” and included fees associated with blood products, screening and testing, service fees, and associated value-added tax; fees associated with clinician services and medical supplies necessary for transfusions were not included.

Data Analysis and Definitions

Analyses were restricted to data from patients with hemoglobin levels available from the time of hospital admission. Admission hemoglobin levels as well as full blood counts, blood chemistry (including creatinine), and the results of all mycobacterial and
of 29 July 2018

By guest

Downloaded from https://academic.oup.com/ofid/article-abstract/2/4/ofv173/2460612

other microbiological investigations were extracted from the National Health Laboratory Service computerized data system. Anemia severity was classified into mutually exclusive groups using admission hemoglobin levels according to a combination of World Health Organization [25] and AIDS Clinical Trials Group (ACTG) [26] criteria. These are as follows: no anemia (≥13.0 g/dL for men, ≥12.0 g/dL for females), mild anemia (11.0–12.9 g/dL for men, 11.0–11.9 g/dL for females), moderate anemia (8.0–10.9 g/dL for males and females), severe anemia (6.5–7.9 g/dL for males and females), and life-threatening anemia (<6.5 g/dL for males and females). Patient case notes and laboratory results were reviewed by 2 investigators (G.M. and A.D.K.) and were used to classify patients into 5 mutually exclusive groups based upon a primary clinical diagnosis: newly diagnosed TB, clinical deterioration of known TB disease, AIDS-defining illness (other than TB), major organ dysfunction/noncommunicable disease, or “other,” as previously described [24]. “Cardiopulmonary illness” was defined by any patient for whom their primary admission diagnosis was related to a cardiac and/or pulmonary disease, including newly diagnosed or worsening TB disease. Creatinine levels upon admission were used to calculate an estimated glomerular filtration rate (eGFR) [27].

For multivariable analyses, a patient was considered to have received a blood transfusion if they were transfused with RCC at any point between 7 days before and 90 days after study entry. All data analyses were conducted using Stata version 12.0 (College Station, TX). Proportions were compared using either Fisher’s exact tests or χ² tests, and medians were compared using either Wilcoxon rank-sum tests or Kruskal–Wallis tests. Multivariable logistic regression analyses were undertaken to identify variables associated with receipt of a blood transfusion. Cox proportional-hazards regression analyses were performed to identify independent predictors of mortality in the first 90 days after study enrollment and specifically to test whether blood transfusions were independently associated with an increased mortality risk. Person-time was accrued from the date of hospital admission until death, LTFU, or censorship of data at 90 days after hospital admission. Two multivariable models were constructed that included receipt of blood transfusions coded as a binary (yes/no), an ordinal (none, 1–3 [low], 4–7 [medium], ≥8 [high]), or a continuous variable (for each unit increase). The first model, “clinical model”, included only prespecified factors most likely to influence a physician to order a blood transfusion (blood hemoglobin level, a cardiopulmonary illness, and renal function). The second model, “fully adjusted,” included prespecified factors (ie, blood hemoglobin level, clinical diagnosis, confirmed mycobacteremia, renal function) and any covariates in the univariable models meeting a predetermined cutoff of P < .1. Likelihood ratio tests were used to investigate statistical hypotheses and interactions between variables. All statistical tests were 2-sided at α = 0.05.

RESULTS

Study Profile

Of 609 patients with confirmed HIV infection, 585 were enrolled, and, of these, 578 (98.8%) had admission hemoglobin levels available and were included in this analysis. Patients were typically young, and the majority were female (Table 1). Approximately 85% of patients were aware of their positive HIV-status on admission, but 36% had not yet commenced ART, and viral load was suppressed in only 31% of all patients. Advanced immunodeficiency was common (median CD4 count, 133 cells/µL), and approximately one half of patients had previously been treated for TB disease (Table 1).

Anemia Diagnoses

The median hemoglobin level was 9.5 g/dL, and 84.8% (n = 490) of all patients were anemic. Anemia was classified as mild, moderate, severe, and life-threatening in 15.7% (n = 91), 38.4% (n = 222), 17.3% (n = 100), and 13.3% (n = 77) of 578 patients, respectively (Table 1). Greater anemia severity was associated with younger age, a new HIV diagnosis, and having started ART within the previous 90 days (Table 1). Those with more severe anemia were also more likely to have more advanced immunodeficiency, higher HIV viral loads, higher CRP levels, and lower eGFRs (Table 1). Lower mean corpuscular values and mean corpuscular hemoglobin values as well as increased red cell distribution widths were also associated with greater severity of anemia. In addition, those with greater anemia severity were more likely to have symptoms suggestive of TB and also have mycobacteremia (Table 1). Only 37 (6.4%) of all patients were receiving a zidovudine (AZT)-containing regimen, and AZT use was not associated with anemia severity.

Clinical Diagnoses Among Patients With Anemia

Patients were classified into 1 of 5 mutually exclusive groups based on their primary diagnosis leading to hospital admission (Table 2). Newly diagnosed TB disease was the most common diagnosis among the overall cohort and accounted for almost half of all diagnoses among those with severe or life-threatening anemia. Approximately one quarter of patients with life-threatening anemia had major organ dysfunction or a noncommunicable disease. Acquired immune deficiency syndrome-defining illnesses other than TB did not constitute a large proportion of those with more severe anemia.

Blood Transfusion Requirements and Associated Costs Among All Patients

Within 90 days after hospital admission and study enrollment, 13.5% (n = 78) of all patients and 15.7% (n = 77) of patients with anemia of any severity at the time of hospital admission received at least 1 blood transfusion with RCC; 61.0% (n = 47) of patients with life-threatening anemia at admission and 16.0% (n = 16) of those with severe anemia at admission were

Blood Transfusions in HIV-Infected Patients • OFID • 3
| Patient characteristics | All Patients, n = 578 (100%) | No Anemia, n = 88 (15.2%) | Mild Anemia, n = 91 (15.7%) | Moderate Anemia, n = 222 (38.4%) | Severe Anemia, n = 100 (17.3%) | Life-threatening Anemia, n = 77 (13.3%) | P Value |
|-------------------------|-------------------------------|---------------------------|-----------------------------|---------------------------------|---------------------------------|---------------------------------|---------|
| Age, median (IQR)       | 35.4 (28.9–41.4)              | 37.4 (30.3–45.2)          | 38.0 (31.2–44.3)            | 34.8 (29.1–41.5)                | 32.9 (27.6–39.2)                | 32.8 (27.3–38.5)                | <.001   |
| Female                  | 333 (57.6)                    | 49 (55.7)                 | 42 (46.2)                   | 137 (61.7)                      | 61 (61.0)                       | 44 (57.1)                       | .134    |
| HIV newly diagnosed     | 91 (15.7)                     | 13 (14.8)                 | 10 (11.0)                   | 27 (12.2)                       | 22 (22.0)                       | 19 (24.7)                       | .023    |
| ART status              |                               |                           |                             |                                 |                                 |                                 |         |
| ART-naive               | 206 (35.6)                    | 35 (39.8)                 | 28 (30.8)                   | 66 (29.7)                       | 43 (43.0)                       | 34 (44.2)                       | .069    |
| Current ART use         | 260 (45.0)                    | 41 (46.6)                 | 47 (51.7)                   | 107 (48.2)                      | 34 (34.0)                       | 31 (40.3)                       | .023    |
| ART interrupted         | 112 (19.4)                    | 12 (13.6)                 | 16 (17.6)                   | 49 (22.1)                       | 23 (23.0)                       | 12 (15.6)                       |         |
| Patient characteristics |                               |                           |                             |                                 |                                 |                                 |         |
| Treatment duration (years), median (IQR) | 1.0 (0.2–2.7)              | 1.8 (0.9–3.9)             | 0.7 (0.2–2.8)               | 0.7 (0.2–2.5)                   | 0.9 (0.2–2.8)                   | 0.7 (0.2–2.2)                   | .081    |
| ART for <90 d           | 67 (26.8)                     | 4 (10.3)                  | 10 (22.7)                   | 32 (31.1)                       | 13 (38.2)                       | 8 (26.7)                        | .048    |
| AZT-containing regimen  | 37 (10.0)                     | 7 (13.2)                  | 6 (9.5)                     | 18 (11.5)                       | 3 (6.3)                         | 3 (6.0)                         | .574    |
| Hematological tests, median (IQR) |                       |                           |                             |                                 |                                 |                                 |         |
| Hemoglobin (g/dL)       | 9.5 (7.6–11.3)                | 13.6 (12.8–14.3)          | 11.5 (11.2–11.8)            | 9.5 (8.8–10.1)                  | 7.5 (6.9–7.7)                   | 5.4 (4.6–6.0)                   | <.001   |
| MCV (fL)                | 89 (83–95)                    | 94 (88–99)                | 91 (86–97)                  | 89 (84–94)                      | 84 (79–91)                      | 85 (79–92)                      | <.001   |
| MCHC (g/dL)             | 32.9 (32.1–33.7)              | 33.5 (32.9–34.2)          | 33.3 (32.6–34.0)            | 32.8 (32.1–33.6)                | 32.7 (31.6–33.3)                | 32.1 (30.9–32.8)                | <.001   |
| RDW (%)                 | 14.5 (12.9–16.3)              | 13.1 (12.5–14.3)          | 13.4 (12.5–15.0)            | 14.6 (13.2–16.1)                | 15.3 (14.1–17.3)                | 16.3 (13.7–18.5)                | <.001   |
| White cell count (x10⁶ cells) | 6.3 (4.6–10.1)              | 6.4 (4.6–10.2)            | 7.3 (5.1–11.1)              | 7.0 (5.1–10.2)                  | 6.5 (3.8–9.2)                   | 7.0 (4.0–10.0)                  | .109    |
| Platelets (x10⁹ cells)  | 260 (188–355)                 | 244 (178–309)             | 270 (206–397)               | 280 (195–356)                   | 235 (175–338)                   | 237 (140–383)                   | <.001   |
| CD4 count (cells/μL), median (IQR) | 133 (53–268)              | 239 (111–459)             | 200 (106–370)               | 129 (53–235)                    | 72 (33–179)                     | 71 (32–190)                     | <.001   |
| Log viral load (copies/mL), median (IQR) | 4.2 (1.6–5.5)              | 3.6 (1.6–5.0)             | 3.7 (1.6–5.2)               | 4.0 (1.6–5.5)                   | 5.4 (3.2–5.9)                   | 4.2 (2.3–5.4)                   | <.001   |
| Viral suppression (viral load<400 copies/mL) | 174 (31.0)              | 34 (39.1)                 | 33 (37.1)                   | 67 (30.6)                       | 17 (18.3)                       | 23 (31.1)                       | .024    |
| CRP (mg/L), median (IQR) | 71 (25–138)              | 21 (7–102)                | 59 (23–119)                 | 73 (28–147)                     | 100 (50–169)                    | 90 (53–142)                     | <.001   |
| Creatinine (μmol/L), median (IQR) | 68 (52–93)              | 70 (54–84)                | 66 (53–83)                  | 65 (51–84)                      | 67 (62–109)                     | 85 (52–194)                     | .028    |
| eGFR classification (mL/min/1.73 m²) |                          |                           |                             |                                 |                                 |                                 |         |
| <30                     | 39 (6.8)                      | 3 (3.5)                   | 0                           | 11 (5.0)                        | 9 (9.0)                        | 16 (20.8)                       | <.001   |
| ≥30                     | 538 (93.2)                    | 84 (96.6)                 | 91 (100)                    | 211 (95.1)                      | 91 (91.0)                       | 61 (79.2)                       |         |
| Tuberculosis            |                               |                           |                             |                                 |                                 |                                 |         |
| Positive WHO symptom screen | 537 (93.2)              | 74 (84.1)                 | 83 (91.2)                   | 208 (94.6)                      | 98 (98.0)                       | 74 (96.1)                       | .003    |
transfused. A total of 246 units were transfused, and the mean number of units per patient was 3.2 (standard deviation = 2.3; range, 1–12); 42.3% (n = 33) of those requiring at least 1 unit of RCC had multiple blood transfusions within 90 days. The cost of RCC alone (n = 246 units) in those requiring a blood transfusion was 192 950 South African Rand (ZAR [$19 523 US dollars at study end date]). When service fees and taxes were included, the total overall cost was 256 370 ZAR ($25 940), and thus the mean cost per patient requiring transfusion was 3287 ZAR ($333).

**Relationship Between Blood Transfusions and Mortality**

Overall, 77 (13.3%) of patients died within 90 days, of which 68 (88.3%) had some degree of anemia; 16.9% (n = 13) had severe and 24.7% (n = 19) had life-threatening anemia, respectively. Of patients receiving a blood transfusion, 26.0% (n = 20) died compared with 11.6% (n = 58) of patients who were not transfused (P < .001). The 20 patients who died despite receiving a transfusion typically had advanced immunodeficiency (median admission CD4 count, 68 cells/µL) and very severe anemia (median hemoglobin level, 6.0 g/dL). In addition, a large proportion had TB disease and additional significant comorbidities (Supplementary Table 1).

In univariable Cox regression analyses, receipt of blood transfusion was associated with increased mortality risk, irrespective of whether it was coded as a binomial, ordinal, or continuous variable (Table 3). However, regardless of how receipt of blood transfusions were coded, in multivariable analyses neither model demonstrated evidence that blood transfusions were associated with a greater risk of mortality (Figure 1). Having an eGFR < 30 (consistent with chronic renal disease) was independently associated with mortality in all multivariable models. Patients with a cardiopulmonary illness or those who were diagnosed with either an AIDS-defining illness or noncommunicable disease or major organ dysfunction also had an independently higher mortality risk. Lower hemoglobin levels were independently associated with poor survival in some but not all multivariable models (Table 1 and Supplementary Table 2).

**Factors Associated With Blood Transfusion in Patients With Severe Anemia**

The median hemoglobin at admission in patients receiving a blood transfusion (n = 78) was 5.9 g/dL. The characteristics of patients who received a transfusion were compared with those of patients who did not; however, to improve clinical relevance, analysis was restricted to those with severe or life-threatening anemia (n = 177). Patients receiving a transfusion were more likely (1) to have higher viral loads, (2) to have been previously treated for TB, (3) to have mycobacteremia, and (4) to have an admission diagnosis related to major organ dysfunction or a noncommunicable disease (Supplementary Table 3). In multivariable models, only lower hemoglobin levels predicted receipt of blood transfusion (Supplementary Table 4).
DISCUSSION

The large majority of HIV-infected adults requiring acute medical admission to a South African district hospital were anemic, and many had either severe or life-threatening anemia. A substantial proportion of such patients received at least 1 blood transfusion, and, cumulatively, this cohort required the administration of a large number of blood products. In contrast to earlier reports from high-income settings, receipt of a blood transfusion was not associated with an increased risk of short-term mortality after adjusting for potential confounding variables.

Although patients requiring a blood transfusion were 2-fold more likely to die in the first 90 days, after adjusting for confounding variables, receipt of blood transfusion was not independently associated with increased mortality. This finding is in contrast with 3 previous reports from the United States showing that short-term mortality risk was increased among HIV-infected patients requiring transfusion [11, 18, 19]. Several theories have been proposed to explain this relationship, including that blood transfusions may cause transient immunosuppression (transfusion immunomodulation), although this is controversial [28]. Although one study found modestly increased viral load among transfused HIV-infected patients, the clinical significance of the small increase in viral load was not determined [20]. In previous studies, it was thought that leukocytes in blood products may (1) directly activate HIV cellular reservoirs, (2) lead to increased proviral transcription, (3) cause immunosuppression, and (4) be associated with greater mortality. However, this was largely disproved by a randomized trial that demonstrated similar HIV-viral loads and survival probabilities among HIV-infected patients receiving nonleukocyte-reduced blood transfusions compared with those receiving leukocyte-reduced blood transfusions [29]. It has also been suggested that blood transfusions may increase mortality by causing iron overload. Although iron excess is associated with increased mortality in sub-Saharan Africa [30], this relationship has not yet been conclusively proven. Finally, transfusion-associated circulatory overload (TACO) may be associated with mortality in HIV-infected patients with chronic severe anemia (especially those with underlying cardiopulmonary disease), but it is a relatively rare clinical phenomenon [12].

We and others suspect that the relationship between receipt of blood transfusion and increased mortality risk reported in previous studies more or less reflects an inherently higher mortality risk among patients with advanced HIV who are likely to be transfused compared with those who are not. In this way, receipt of a blood transfusion serves as a marker of overall disease severity and mortality risk. Therefore, decreased survival may simply represent confounding by indication [31]. In our study, 20 patients died after receiving a transfusion, and such patients were extremely ill, with advanced HIV disease, often had disseminated TB disease, and most had several concomitant copathologies. We carefully considered covariates possibly confounding the relationship between blood transfusions and mortality and adjusted for them accordingly. Even after doing so, there was no evidence to suggest that an independent association existed between blood transfusion and greater mortality, regardless of whether receipt of a transfusion was coded as a binary, ordinal, or continuous variable. Previous studies in which the relationship between transfusion and poor survival persisted despite adjusting for potential confounders may also have had residual confounding that is present to some degree in all observational studies [31]. This possibility is partially supported by the finding that an independent relationship between blood transfusions and higher mortality among AIDS patients in New York did not persist after further adjusting for illness.
severity [18]. If present in our study, residual confounding is probably accounted for by unrecorded markers of disease severity, and if a further adjustment were possible, it would likely be in favor of finding transfusions to not adversely affect prognosis. Unmeasured confounders may possibly even mask a clinical benefit associated with receipt of blood transfusions.

In this patient population, which included patients who were ART-naive and those receiving ART, 85% had anemia, and the prevalence of severe or life-threatening anemia was more than 30%. Previous studies in sub-Saharan Africa have also reported a similarly high prevalence of HIV-related anemia, sometimes approaching as high as 90% [3, 5, 6, 32]; however, such estimates are largely derived among ART-naive, ambulatory outpatients. The high prevalence of severe or life-threatening anemia observed in this study was in part due to the inclusion of patients ill enough to seek acute medical attention, as well as advanced

| Table 3. Cox Multivariable Analysis for Risk Factors Associated With Mortality (Blood Transfusion Coded as a Binary Variable) |
|---------------------------------------------------------------|
| **Unadjusted HR (95% CI)** | **P Value** | **“Clinical Model” Adjusted HR (95% CI)** | **P Value** | **“Classic Model” Adjusted HR (95% CI)** | **P Value** |
| Age, for each year increase | 1.00 (.98–1.02) | .961 | 1.00 (.98–1.03) | .834 |
| Male | 1.02 (.65–1.60) | .936 | .81 (.48–1.36) | .415 |
| ART status | | | | | |
| Current use | 1.0 | | | | |
| Naive | 1.02 (.62–1.69) | | | | |
| Defaulted | 1.13 (.62–2.05) | | | | |
| Previous history of TB treatment | | | | | |
| No | 1.0 | .800 | | | |
| Yes | 0.94 (.60–1.48) | | | | |
| History of shortness of breath | | | | | |
| No | 1.0 | .733 | | | |
| Yes | 1.08 (.69–1.69) | | | | |
| CD4 (cells/μL), for every 50-unit decrease | 1.10 (1.02–1.19) | .004 | 1.06 (.97–1.15) | .186 |
| Viral load (copies/mL), for each log-unit increase | 0.99 (.87–1.13) | .871 | | | |
| Hemoglobin (g/dL), for each unit decrease | 1.15 (1.06–1.25) | .001 | 1.08 (.98–1.19) | .096 |
| CRP (mg/L), for each 10-unit increase | 1.03 (1.01–1.06) | .007 | 1.03 (1.00–1.06) | .050 |
| eGFR category (mL/min/1.73 m²) | | | | | |
| eGFR ≥30 | 1.0 | | 1.0 | | |
| eGFR<30 | 3.72 (2.08–6.64) | .001 | 3.04 (1.65–5.59) | | |
| Confirmed mycobacteremia | | | | | |
| No | 1.0 | | 1.0 | | |
| Yes | 1.82 (.94–3.53) | | 1.97 (.78–4.93) | | |
| Clinical Diagnosis | | | | | |
| “Other” | 1.0 | | 1.0 | | |
| New TB | 1.10 (.59–2.05) | | 0.68 (.30–1.52) | | |
| Deterioration of TB | 1.00 (.34–2.94) | | 1.03 (.33–3.21) | | |
| AIDS-defining illness (other than TB) | 3.40 (1.80–6.43) | | 3.40 (1.62–7.16) | | |
| NCD/MOD | 1.84 (.92–3.67) | | 2.33 (1.05–5.14) | | |
| Cardiopulmonary illness | | | | | |
| Yes | 1.0 | | 1.0 | | |
| No | 1.57 (1.00–2.49) | | 1.67 (1.05–2.64) | | |
| Received a blood transfusion | | | | | |
| No | 1.0 | | 1.0 | | |
| Yes | 2.34 (1.41–3.89) | | 1.40 (.75–2.63) | | |

Abbreviations: ART, antiretroviral therapy; CI, confidence interval; CRP, C-reactive protein; eGFR, estimated glomerular filtration rate; HR, hazards ratio; MOD, major organ dysfunction; NCD, noncommunicable disease; TB, tuberculosis.

* There was no evidence for interaction between receipt of blood transfusion and duration of follow-up (time).
HIV/AIDS disease, and a high rate of opportunistic infections, notably TB. Newly diagnosed TB was the primary diagnosis for more than one third of all patients and accounted for nearly one half of diagnoses among patients with severe or life-threatening anemia. These results are entirely consistent with a study from Malawi in which 43% of hospitalized HIV-infected patients with severe anemia had TB [33] and provide further evidence to suggest that anemia might have high predictive value for HIV-associated TB in high-incidence settings [32, 34, 35]. In addition, patients in our study often had advanced HIV illness with opportunistic infection or major organ dysfunction. Thus, malignancies, nutritional deficiencies, and drug toxicities may all have further contributed to the high observed prevalence and severity of anemia [36].

The large number of blood transfusions received by hospitalized, HIV-infected adults in the present study builds upon a previous report from South Africa which demonstrated that HIV-infected inpatients have higher transfusion requirements than HIV-uninfected patients from the same hospital setting and that such patients utilized a large number of blood products [16]. In the present study, despite a large proportion of patients being transfused, it is unclear whether patients had adequate transfusion support because some patients with life-threatening anemia were not transfused, and many of those who were transfused received only 1–2 units of RCC. This may reflect several factors, including patients presenting late to medical care in extremis and dying before transfusion and also that physicians often prescribe blood transfusions based on a patient’s composite clinical picture and not hemoglobin level alone. There was not a standardized institutional protocol for blood transfusions; thus, some of these discrepancies are partially influenced by variability in transfusion practice between doctors, departments, and hospitals. In addition, a perception by local physicians of a shortage in supplies of blood products and their high cost may have resulted in blood products being used sparingly by some.

In many clinical settings in sub-Saharan Africa, there is a shortage of “safe” blood products [37]. Although South Africa has greater healthcare resources than most countries of sub-Saharan Africa, inadequate quantities of blood is often still a reality [38]. In this cohort, blood transfusions for 78 patients accrued a cost of more than $25 000, which is likely an underestimate because this estimate did not include associated private clinician’s fees and associated medical supplies, and thus transfusions are associated with substantially increased overall healthcare expenditure [39]. In view of these facts, improved

---

Figure 1. Adjusted hazard ratios and associated 95% confidence intervals for mortality stratified by blood transfusion status. aModel #1 (clinical model) adjusted for hemoglobin concentration, cardiopulmonary illness status, and renal function (estimated glomerular filtration rate <30 mL/min/1.73 m²; yes or no). bModel #2 (fully adjusted model) adjusted for age, gender, CD4 cell count, hemoglobin concentration, C-reactive protein concentration, renal function (eGFR <30; yes or no), mycobacterial blood culture result, and primary clinical diagnosis category. The comparator group for all analyses was those who did not receive a blood transfusion.
solutions are needed to not only increase the availability of safe and affordable blood products but also to reduce unnecessary blood transfusions and to reduce requirements for blood products [37]. In this study, neither current ART use nor viral suppression was associated with a decreased likelihood of blood transfusion. However, patients requiring hospitalization despite ART use and viral suppression are a minority and are not likely representative of those receiving ART in the larger community. Antiretroviral therapy is strongly associated with the resolution of anemia in a majority of patients [3, 5, 6, 13, 14], and a previous study found that ART was associated with decreased blood transfusion requirements [40]. Thus, increased ART coverage may contribute towards decreased patient morbidity, the increased availability of blood products, and decreased healthcare costs. Prescription of blood transfusions should be based on best practice guidelines where available [12], and further studies are needed to evaluate the impact of ART on blood product use (especially large ART cohort studies), as well as additional strategies for reducing blood transfusion requirements among both HIV-infected and uninfected patients in sub-Saharan Africa [15, 41].

Strengths of this study include that this was a well characterized, prospectively recruited cohort that enrolled all HIV-infected hospitalized adults requiring acute medical admission regardless of reason for admission. An additional strength was a high ascertainment rate of vital status with <6% LTFU, despite lack of routine follow-up in outpatient care. Nevertheless, mortality was possibly underestimated because a proportion of patients LTFU may have died. We comprehensively searched for transfusion requirements; however, the proportion of patients transfused and their corresponding blood product use was likely underestimated as patients occasionally report different names or identifying information and may have presented to healthcare settings outside of the study hospital. This study was conducted at a single site, and there was a relatively small number of transfusions and patient deaths. It should also be noted that although the lack of an independent association between blood transfusions and mortality is likely to be generalizable to other inpatient settings in sub-Saharan Africa, the proportion of patients receiving blood transfusions and the associated use of blood products represent point estimates and will undoubtedly vary across different settings for a number of reasons, including variability in blood transfusion prescription practices. Therefore, the transfusion requirements among patients in this study should not be extrapolated to other settings.

CONCLUSIONS

More than 30% of HIV-infected hospitalized patients had severe or life-threatening anemia, which resulted in a high proportion of patients requiring a blood transfusion. Receipt of a blood transfusion was not independently associated with greater mortality risk. Thus, we found no evidence to support concerns regarding the potential adverse impact of the administration of blood transfusions to HIV-infected adults in sub-Saharan Africa.

Supplementary Material

Supplementary material is available online at Open Forum Infectious Diseases (http://OpenForumInfectiousDiseases.oxfordjournals.org/).

Acknowledgments

The investigators are grateful to the staff at G. F. Jooste Hospital and also to the Provincial Government of the Western Cape for granting permission for this study. The authors thank Caren Overall and Kevin De Smidt at the Red Cross Blood Bank for help in ascertaining patients’ blood transfusion requirements.

Author contributions. A. D. K., G. M., and S. D. L. designed the study. A. D. K. was responsible for the database. S. D. L., G. M., and R. B. were responsible for the patient cohort. A. D. K., G. M., and S. D. L. designed the analyses. A. D. K. performed the analyses with input from F. J. C. A. D. K., C. S., and A. B. ascertained patient outcomes. A. D. K. wrote the first draft of the paper. G. M., S. D. L., and F. J. C. gave input to further drafts. All other authors commented on a draft and approved the final version of the article.

Disclaimer. The funders had no role in the study design, data collection, data analysis, data interpretation, or writing of this report. The opinions, findings and conclusions expressed in this manuscript reflect those of the authors alone.

Financial support. The study was funded by the Wellcome Trust. S. D. L. and G. M. are funded by the Wellcome Trust (London, UK) (Grant numbers 088590, 098316, and 085251). S. D. L. is also funded by a Global Clinical Trials grant from the Medical Research Council/Department for International Development/Wellcome Trust (Grant number MR/M007375/1). G. M. was also supported in part by the National Research Foundation of South Africa (Grant number UID 85858).

Potential conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

References

1. Akinkuotu A, Roemer E, Richardson A, et al. In-hospital mortality rates and HIV: a medical ward review, Lilongwe, Malawi. Int J STD AIDS 2011; 22:465–70.
2. Lewden C, Drabo JY, Zannou MD, et al. Disease patterns and causes of death of hospitalized HIV-positive adults in West Africa: a multicountry survey in the antiretroviral treatment era. J Int AIDS Soc 2014; 17:12.
3. Johannessen A, Naman E, Gundersen SG, Bruun JN. Antiretroviral treatment reverses HIV-associated anemia in rural Tanzania. BMC Infect Dis 2011; 11:190.
4. O’Brien ME, Kuppa R, Msamanga GI, et al. Anemia is an independent predictor of mortality and immunologic progression of disease among women with HIV in Tanzania. J Acquir Immune Defic Syndr 2005; 40:219–25.
5. Kerkhoff AD, Wood R, Cobelens FG, et al. Resolution of anaemia in a cohort of HIV–infected patients with a high prevalence and incidence of tuberculosis receiving antiretroviral therapy in South Africa. BMC Infect Dis 2014; 14:702.
6. Parrish DD, Blewins M, Megazzini KM, et al. Haemoglobin recovery among HIV-1 infected patients on zidovudine-based antiretroviral therapy and other regimens in north-central Nigeria. Int J STD AIDS 2014; 25:355–9.
7. Volberding P. The impact of anemia on quality of life in human immunodeficiency virus-infected patients. J Infect Dis 2002; 185:S110–4.
8. Harris RJ, Sterne JA, Abgrall S, et al. Prognostic importance of anemia in HIV type-1-infected patients starting antiretroviral therapy.
11. Moore RD, Keruly JC, Chaisson RE. Anemia and survival in HIV infection. J Acquir Immune Defic Syndr 1998; 19:29–33.

12. Van den Berg K, Van Hasselt J, Bloch E, et al. A review of the use of blood and blood products in HIV-infected patients: review. S Afr HIV Med 2012; 13:87–103.

13. Moore RD, Forney D. Anemia in HIV-infected patients receiving highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2002; 29:54–7.

14. Takuvu S, Maskew M, Brennan AT, et al. Anemia among HIV-infected patients initiating antiretroviral therapy in South Africa: improvement in hemoglobin regardless of degree of immunosuppression and the initiating ART regimen. J Trop Med 2013; 2013:1–6.

15. van den Berg K, Murphy EL, Pretorius L, Louw VI. The impact of HIV-associated anemia on the incidence of red blood cell transfusion: Implications for blood services in HIV-endemic countries. Transfus Apher Sci 2014; 51:10–8.

16. Ntusi NBA, Sonderup MW. HIV/AIDS influences blood and blood product use at Groote Schuur Hospital, Cape Town. S Afr Med J 2011; 101:463–6.

17. Butler EK, Hume H, Birungi I, et al. Blood utilization at a national referral hospital in sub-Saharan Africa. Transfusion 2015; 55:1058–66.

18. Vamvakas E, Kaplan HS. Early transfusion and length of survival in acquired immune deficiency syndrome: experience with a population receiving medical care at a public hospital. Transfusion 1993; 33:111–8.

19. Buskin SE, Sullivan PS. Anemia and its treatment and outcomes in persons infected with human immunodeficiency virus. Transfusion 2004; 44:826–32.

20. Mudido PM, Georges D, Dorazio D, et al. Human immunodeficiency virus type 1 activation after blood transfusion. Transfusion 1996; 36:880–5.

21. Gupta A, Wood R, Kaplan R, et al. Prevalent and incident tuberculosis are independent risk factors for mortality among patients accessing antiretroviral therapy in South Africa. PLoS One 2013; 8:e55824.

22. Lawn SD, Myer L, Bekker LG, Wood R. Burden of tuberculosis in an antiretroviral treatment programme in sub-Saharan Africa: impact on treatment outcomes and implications for tuberculosis control. AIDS 2006; 20:1605–12.

23. Lawn SD, Kerkhoff AD, Burton R, et al. Rapid microbiological screening for tuberculosis in HIV-positive patients on the first day of acute hospital admission by systematic testing of urine samples using Xpert MTB/RIF: a prospective cohort in South Africa. BMC Med 2015; 13:192.

24. Meintjes G, Kerkhoff AD, Burton R, et al. HIV-Related Medical Admissions to a South African District Hospital Remain Frequent Despite Effective Antiretroviral Therapy Scale-Up. Medicine (Baltimore); 2015; 94:e2269.

25. World Health Organization. Haemoglobin concentrations for the diagnosis of anemia and assessment of severity. Geneva; 2011. Available at: http://www.who.int/iris/bitstream/10665/85839/http://apps.who.int/iris/bitstream/10665/85839/1/WHo NMH_NHD_MNM_11.1_eng. pdf?ua=1. Accessed: 07/27/2015.

26. National Institutes of Health. Division of AIDS table for grading the severity of adult and pediatric adverse events, version 1.0. 2009 :1–21. Available at: http://rsc.tech-res.com/document/safetyandpharmacovigilance/table_for_grading_severity_of_adult_pediatric_adverse_events.pdf. Accessed: 27 July 2015.

27. Leve AS, Coresh J, Greene T, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 2006; 145:247–54.

28. Hillyer CD, Lankford KV, Roback JD, et al. Transfusion of the HIV-seropositive patient: immunomodulation, viral reactivation, and limiting exposure to EBV (HHV-4), CMV (HHV-5), and HHV-6, 7, and 8. Transfus Med Rev 1999; 13:1–17.

29. Collier AC, Kalish LA, Busch MP, et al. Leukocyte-reduced red blood cell transfusions in patients with anemia and human immunodeficiency virus infection: the viral activation transfusion study: a randomized controlled trial. JAMA 2001; 285:592–601.

30. McDermid JM, Jaye A, Schim van der Loef MF, et al. Elevated iron status strongly predicts mortality in West African adults with HIV infection. J Acquir Immune Defic Syndr 2007; 46:498–507.

31. Psaty BM, Koepsell TD, Lin D, et al. Assessment and control for confounding by indication in observational studies. J Am Geriatr Soc 1999; 47:749–54.

32. Lewis DK, Whitby CJ, Walsh AL, et al. Treatable factors associated with severe anemia in adults admitted to medical wards in Blantyre, Malawi, an area of high HIV seroprevalence. Trans R Soc Trop Med Hyg 2005; 99:561–7.

33. Kerkhoff AD, Wood R, Vogt M, Lawn SD. Predictive value of anemia for tuberculosis in HIV-infected patients in sub-Saharan Africa: an indication for routine microbiological investigation using new rapid assays. J Acquir Immune Defic Syndr 2014; 66:33–40.

34. Masai A, Gahutu JB, Mukiibi J, et al. Anemia in human immunodeficiency virus infection: the viral activation transfusion study: a randomized controlled trial. JAMA 2001; 285:1592–601.

35. Ogunbanjo G. Are there alternatives to the shortage of blood in South Africa? S Afr Fam Pract 2011; 102:465–8.

36. Ope J. Haematological complications of HIV infection. S Afr Med J 2012; 102:465–8.

37. Osaro E, Adias T. The challenges of meeting the blood transfusion requirements in Sub-Saharan Africa: the need for the development of alternatives to allo genic blood. J Blood Med 2011; 2:7–21.

38. Ogunbanjo G. Are there alternatives to the shortage of blood in South Africa? S Afr Fam Pract 2014; 56:i–i.

39. Lara AM, Kandulu J, Chisuwo L, et al. Laboratory costs of a hospital-based blood transfusion service in Malawi. J Clin Path 2007; 60:1117–20.

40. Murphy EL, Collier AC, Kalish LA, et al. Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease. Ann Intern Med 2001; 135:17–26.

41. Ifland L. Promoting national blood systems in developing countries. Curr Opin Hematol 2014; 21:497–502.